Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BUZZ - Artificial intelligence infrastructure company Accelevation is set to debut on Nasdaq after pricing its IPO below the range.

BUZZ - Artificial intelligence infrastructure company Accelevation is set to debut on Nasdaq after pricing its IPO below the range.

路透社路透社2026/09/30 14:31
Show original

- ** Artificial intelligence infrastructure company Accelevation Holdings (ACCV.O) is scheduled to list on Nasdaq on Wednesday, after its IPO was priced below expectations

** The stock most recently indicated an opening price of $18.05, compared to an issue price of $18

** The Miamisburg, Ohio-based company and its shareholders sold (link) 30 million shares on Tuesday evening, at a price far below the $20 to $24 range (link), raising $540 million

** ACCV issued 10 million shares; some selling shareholders affiliated with private equity firm Olympus Partners offloaded 20 million shares

** ACCV proceeded with the offering despite increasingly challenging market conditions (link), as soaring bond yields and tightening interest rate environments have dampened market risk appetite

** On Tuesday, the window for autumn IPOs continued to narrow, with smart ring maker Oura becoming the latest U.S. IPO candidate to delay its listing plans (link)

** Founded in 2017, ACCV designs, manufactures, and installs power distribution, cooling, and modular infrastructure for data center clients

** Olympus Partners will hold 85% of the voting rights after acquiring ACCV last year from private equity firm LFM Capital

** Morgan Stanley and JPMorgan are leading an 11-firm underwriting syndicate for the IPO


(To facilitate non-native English speakers, Reuters has automatically translated its reports into several other languages. As automated translations may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of the automated translation and provides it only for readers’ convenience. Reuters assumes no responsibility for any damage or loss caused by the use of automated translation.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Roche (RHHBY.US) BTK inhibitor submitted for listing

On September 30, Roche (RHHBY.US) announced that the U.S. FDA has accepted the New Drug Application (NDA) for its non-covalent BTK inhibitor, fenebrutinib.

智通财经•2026/09/30 15:26